Telithromycin in Acute Exacerbation of Chronic Bronchitis

Bronchitis, Chronic Clinical Trial

Official title:

Multicenter Non Comparative Phase IV Study on the Safety and Efficacy of Telithromycin 800 mg Per Day for 5 Days in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adults

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00288223
• Other study ID #: HMR3647A_4022
• Status: Terminated
• Phase: Phase 4
• First received: February 6, 2006
• Last updated: December 8, 2009
• Start date: January 2006
• Est. completion date: January 2007

Study information

• Verified date: December 2009
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: Turkey: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Study objectives:

• to document the clinical efficacy of telithromycin(800 mg per day for 5 days) at Test Of the Cure (TOC)visit (D12-D19), in acute exacerbation of chronic bronchitis.

• to assess the long-term clinical efficacy of telithromycin by telephone at D25-D35 (V3)

• to assess the safety of telithromycin

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 54
• Est. completion date: January 2007
• Est. primary completion date: January 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 35 Years and older

Eligibility

Inclusion Criteria:

• Outpatients,

• With a documented history of chronic bronchitis defined by one expectoration daily for at least three consecutive months over at least two consecutive years

• Presenting with an evident acute exacerbation of their disease defined by the presence of at least two of Anthonisen's criteria:

• exacerbation of dyspnea,

• increase in the expectoration volume,

• increase in the expectoration purulence,

Exclusion Criteria:

• Acute bronchitis,

• Chronic obstructive pulmonary disease, those having FEV1 value <35% (FEV1: Forced Expiratory Volume in 1 second)

• Suspected pneumonia or bronchial pneumonia,

• Paroxysmal asthma or continuous dyspnea in asthma,

• Cystic fibrosis,

• Active tuberculosis,

• Lung cancer or lung metastasis,

• Severe bronchiectasia,

• Acute respiratory decompensation,

• Chronic respiratory insufficiency associated with resting hypoxemia,

• Patients requiring hospitalization for parenteral antibiotic treatment

• Patients with suspected or known bacterial infection other than study diseases, as well as associated systemic or intra-tracheal antibiotic treatment other than study treatment,

• Participating in another clinical study with any product within 30 days before the inclusion of study

• Known immunosuppression (AIDS and/or CD4+ lymphocytes < 200/mm3, neutropenia <1500/mm3, blood diseases or terminal stage cancer)

• Cardiovasculary, neurologic or other severe diseases interfering with the compliance with study protocol or confusing with results.

Conditions associated with study medications:

• Hypersensitivity against telithromycin , macrolides or any of the excipients,

• Congenital long QT syndrome or family history of congenital long QT syndrome (this possibility should be excluded with normal ECG) or known acquired QT interval prolongation,

• Treatment with CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, phenobarbital, St-John's-wort) within 2 weeks prior to the study inclusion

• Possibility of treatment with ergot alkaloid derivatives, terfenadine, astemizole, pimozide, cisapride, simvastatin, athorvastatin or lovastatin during studies

• Congenital galactosemia, lactase deficiency glucose or galactose malabsorption syndrome,

• Pregnant or lactating women,

• Women with childbearing potential (e.g. ovulating, pre-menopausal or not surgically sterilized) and do not employ any effective contraception method The patients may not participate to the study more than once. The patients who were treated with study drugs previously may not participate to the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Bronchitis
• Bronchitis, Chronic

Intervention

Drug:
• Telithromycin
one daily intake of 800 mg (i.e. 2 x 400 mg tablets) per os in a single intake with a meal for 5 days.

Locations

Country	Name	City	State
Turkey	Sanofi-Aventis	Istanbul

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of clinical success (cure + improvement) at TOC visit (D12-19),clinical success at TOC visit in at risk sub-populations, clinical success at follow up visit (D25-35), reinfection rates,discontinuation of treatment rates, compliance		D12-D19 (efficacy assessment) and D25-D35 (telephone follow-up)	No
Secondary	Safety assessment of telithromycin (Safety will be assessed on the basis of serious and non serious adverse events)		At V3	No